SFPH proteins as therapeutic targets for a myriad of diseases
- Bioorg Med Chem Lett. 2020 Nov 15;30(22):127600. doi: 10.1016/j.bmcl.2020.127600.
Affiliations
- 1. Sino-French Joint Lab of Food Nutrition/Safety and Medicinal Chemistry, College of Biotechnology, Tianjin University of Science and Technology, Tianjin, China.
- 2. INSERM-University of Strasbourg, Regenerative Nanomedicine Laboratory (UMR1260), Faculty of Medicine, FMTS, Strasbourg, France.
- 3. Superior National School Biotechnology Taoufik Khaznadar, Constantine, Algeria.
- 4. University of Batna 2, Faculty of Biology, Batna, Algeria.
- 5. University of Strasbourg, CNRS, IBMP UPR 2357, Strasbourg, France.
- 6. Sino-French Joint Lab of Food Nutrition/Safety and Medicinal Chemistry, College of Biotechnology, Tianjin University of Science and Technology, Tianjin, China; INSERM-University of Strasbourg, Regenerative Nanomedicine Laboratory (UMR1260), Faculty of Medicine, FMTS, Strasbourg, France. Electronic address: [email protected].
PMID: 33035678
DOI: 10.1016/j.bmcl.2020.127600
Abstract
The stomatin/prohibitin/flotillin/HflK/HflC (SPFH) domain is present in an evolutionarily conserved family of proteins that regulate a myriad of signaling pathways in archaea, bacteria and eukaryotes. The most studied SPFH proteins, prohibitins, have already been targeted by different families of small molecules to induce Anticancer, cardioprotective, anti-inflammatory, Antiviral, and antiosteoporotic activities. Ligands of Other SPFH proteins have also been identified and shown to act as anesthetics, anti-allodynia, Anticancer, and anti-inflammatory agents. These findings indicate that modulators of human or Bacterial SPFH proteins can be developed to treat a wide variety of human disorders.
Keywords
Allodynia; Anesthesia; Cancer; Drug discovery; Infectious diseases; Lipid rafts; Scaffold proteins.